To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

However, even established players have struggled. In its Q3 results, GSK (GSK), the first to receive U.S. approval for an RSV ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

全球首家公布RSV候选疫苗与已获批重磅RSV疫苗头对头临床试验结果、且结果积极的厂家，来自中国。当开年至今无一款国产创新型疫苗获批上市，二类疫苗又几乎迎来全员内卷、“价格战”四处打响时，中国创新疫苗行业终于传来了一则好消息：一款国产呼吸道合胞病毒（R ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.